UT Texas Natalizumab treated and Untreated MS Patients.

1Age assessed at time of enrollment in this study. 2EDSS assessed at time of enrollment in this study. 3N/A = Not applicable. Patient started natalizumab after initial approval by the Food and Drug Administration. 4AFFIRM = Natalizumab safety and efficacy in relapsing remitting multiple sclerosis. 5SENTINEL = The safety and efficacy of natalizumab in combination with interferon beta-1a in patients with relapsing-remitting multiple sclerosis RRMS = relapsing-remitting multiple sclerosis; PPMS = primary progressive multiple sclerosis; SPMS = secondary progressive multiple sclerosis; CIS-ON = clinically isolated syndrome/optic neuritis; ND = not determined.